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Repositioning of the global epicentre of 
non-optimal cholesterol
NCD Risk Factor Collaboration (NCD-RisC)*
High blood cholesterol is typically considered a feature of wealthy western 
countries1,2. However, dietary and behavioural determinants of blood cholesterol are 
changing rapidly throughout the world3 and countries are using lipid-lowering 
medications at varying rates. These changes can have distinct effects on the levels of 
high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have 
different effects on human health4,5. However, the trends of HDL and non-HDL 
cholesterol levels over time have not been previously reported in a global analysis. 
Here we pooled 1,127 population-based studies that measured blood lipids in 
102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 
in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there 
was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net 
effect of increases in low- and middle-income countries, especially in east and 
southeast Asia, and decreases in high-income western countries, especially those in 
northwestern Europe, and in central and eastern Europe. As a result, countries with 
the highest level of non-HDL cholesterol—which is a marker of cardiovascular risk—
changed from those in western Europe such as Belgium, Finland, Greenland, Iceland, 
Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific,  
such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL 
cholesterol was responsible for an estimated 3.9 million (95% credible interval 
3.7 million–4.2 million) worldwide deaths, half of which occurred in east, southeast 
and south Asia. The global repositioning of lipid-related risk, with non-optimal 
cholesterol shifting from a distinct feature of high-income countries in northwestern 
Europe, north America and Australasia to one that affects countries in east and 
southeast Asia and Oceania should motivate the use of population-based policies and 
personal interventions to improve nutrition and enhance access to treatment 
throughout the world.
Blood cholesterol is one of the most important risk factors for ischaemic 
heart disease (IHD) and ischaemic stroke4–6. Consistent and comparable 
information on cholesterol levels and trends in different countries can 
help to benchmark national performance in addressing non-optimal 
cholesterol, investigate the reasons behind differential trends and 
identify countries in which interventions are needed the most.
A previous global analysis7 reported trends in total cholesterol 
from 1980 to 2008, but did not analyse important lipid fractions—
including HDL and non-HDL cholesterol—that are key to understand-
ing the cardiovascular disease risk associated with non-optimal 
cholesterol. Dietary and behavioural determinants of cholesterol 
have changed throughout the world in the past decades, including 
a worldwide rise in adiposity8,9, divergent global trends in alcohol 
use10, a rise in the intake of animal-source foods in middle-income 
countries (especially in east Asia)3,11, and a replacement of saturated 
fats and trans fats with unsaturated fats in some high-income coun-
tries3,11,12. There is also considerable variation in how much different 
countries have adopted lipid-lowering medications13. These changes 
are likely to have influenced cholesterol levels substantially in the 
decade since the last estimates were made. Furthermore, HDL and 
non-HDL cholesterol, which have opposite associations with cardio-
vascular diseases4,5, respond differently to diet and treatment, and 
may therefore have different geographical patterns and trends over 
time14. Information on these major lipid fractions, which were not 
included in the previous global estimates, is essential for priority 
setting and intervention choice.
Here we pooled 1,127 population-based studies that measured blood 
lipids in 102.6 million individuals aged 18 years and older (Extended 
Data Figs. 1, 2 and Supplementary Table 1) and used a Bayesian hierarchi-
cal model to estimate trends from 1980 to 2018 in mean total, non-HDL 
and HDL cholesterol levels for 200 countries. We also estimated 
the number of deaths caused by IHD and ischaemic stroke that were 
attributable to high levels of non-HDL cholesterol using information 
on its hazards from epidemiological studies.
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Trends in total cholesterol
In 2018, global age-standardized mean total cholesterol was 4.6 mmol l−1 
(95% credible interval, 4.5–4.7) for women and 4.5 mmol l−1 (4.3–4.6) 
for men. Global age-standardized mean total cholesterol changed 
little over these nearly four decades, decreasing by 0.03 mmol l−1 per 
decade (−0.02–0.08) in women and 0.05 mmol l−1 per decade (0.00–
0.11) in men (posterior probability of the observed declines being true 
declines = 0.90 for women and 0.98 for men) (Fig. 1). Regionally, total 
cholesterol decreased the most in high-income western regions and 
in central and eastern Europe. The decrease was the largest (around 
0.3 mmol l−1 per decade; posterior probability >0.9999) in northwest-
ern Europe, where mean total cholesterol levels had been the high-
est in 1980. The decrease in total cholesterol in high-income western 
regions and central and eastern Europe was largely due to a decline 
in non-HDL cholesterol (Extended Data Fig. 4), which among women 
was offset partly by an increase in mean HDL cholesterol levels. Mean 
total cholesterol changed little in most of the other regions, with the 
notable exception of east and southeast Asia, where it increased by 
more than 0.1 mmol l−1 per decade in both women and men (posterior 
probability ≥0.95). The increase in east and southeast Asia was largely 
due to an increase in non-HDL cholesterol.
Trends in non-HDL and HDL cholesterol
In 2018, global age-standardized mean non-HDL cholesterol was 
3.3 mmol l−1 (3.2–3.4) for women and 3.3 mmol l−1 (3.3–3.4) for men; 
global age-standardized mean HDL cholesterol was 1.3 mmol l−1 (1.2–1.3) 
for women and 1.1 mmol l−1 (1.1–1.2) for men. Global age-standardized 
mean non-HDL cholesterol remained almost unchanged from 1980 to 
2018, decreasing by only 0.02 mmol l−1 per decade (−0.02–0.06; poste-
rior probability = 0.80) in women and 0.01 mmol l−1 per decade (−0.03–
0.06; posterior probability = 0.72) in men. Global age-standardized 
mean HDL cholesterol remained unchanged for women and decreased 
slightly for men (by 0.02 mmol l−1 per decade, posterior probabil-
ity = 0.91).
Regionally, non-HDL cholesterol decreased substantially in 
high-income western regions and central and eastern Europe. The 
largest decrease occurred in northwestern Europe (>0.3 mmol l−1 
per decade; posterior probability >0.9999) (Fig. 2). By contrast, it 
increased in east and southeast Asia, parts of sub-Saharan Africa and 
Melanesia. The increase was the largest in southeast Asia, increasing by 
approximately 0.2 mmol l−1 per decade (posterior probability >0.9999). 
Mean HDL cholesterol increased in the high-income Asia–Pacific region, 
by as much as 0.1 mmol l−1 per decade in women (posterior probabil-
ity >0.9999) but decreased in Melanesia, Polynesia and Micronesia 
(Extended Data Fig. 3).
Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland 
and Malta had some of the highest non-HDL cholesterol levels in 1980 
(>4.5 mmol l−1 in women and >4.7 mmol l−1 in men) but experienced 
some of the largest declines (Figs. 3, 4). At the extreme, mean non-HDL 
cholesterol declined by around 0.45 mmol l−1 per decade or more in 
Belgian and Icelandic women and men, changing their ranks from being 
in the top 10 countries in terms of non-HDL cholesterol in 1980 to being 
ranked in the lower half of the countries in 2018—below countries in 
southwestern Europe such as France and Italy. The largest increases 
were found in east Asian countries (for example, China) and southeast 
Asian countries (for example, Indonesia, Thailand, Malaysia, Cambodia 
and Lao PDR). In these countries, age-standardized mean non-HDL 
cholesterol increased by as much as 0.23 mmol l−1 per decade. As a result 
of these opposite trends, countries with the highest age-standardized 
mean non-HDL cholesterol levels in 2018 were all outside northwestern 
Europe: Tokelau, Malaysia, The Philippines and Thailand, all of which 
had mean non-HDL cholesterol around or above 4 mmol l−1. China, which 
had one of the lowest mean non-HDL cholesterol levels in 1980, reached 
or surpassed non-HDL cholesterol levels of many high-income western 
countries in 2018. Sub-Saharan African countries had the lowest mean 
non-HDL cholesterol in 2018, as low as 2.6 mmol l−1 in some countries, 
as they had in 1980. Not only did high-income countries benefit from 
decreasing non-HDL cholesterol levels, they had higher mean HDL cho-
lesterol than low- and middle-income countries (Extended Data Fig. 6).
Deaths attributable to non-optimal cholesterol
In 2017, high non-HDL cholesterol was responsible for an estimated 
3.9 million (3.7–4.2 million) worldwide deaths from IHD and ischaemic 
stroke (Fig. 5), accounting for a third of deaths from these causes. From 
1990 to 2017, the number of deaths caused by IHD and ischaemic stroke 
that were attributable to high non-HDL cholesterol increased by around 
910,000 globally. This increase was a net result of a large decrease in 
western countries, from 950,000 (890,000–990,000) to 480,000 
(430,000–530,000), and a large increase throughout Asia. In particular, 
the number of deaths attributable to high non-HDL cholesterol more 
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Fig. 1 | Change in age-standardized mean total cholesterol between 1980 
and 2018 by region for women and men. a, Age-standardized mean total 
cholesterol in women. b, Age-standardized mean total cholesterol in men.  
The start of the arrow shows the level in 1980 and the head indicates the level in 
2018. See Extended Data Fig. 3 for age-standardized mean HDL cholesterol. 
One mmol l−1 is equivalent to 38.61 mg dl−1.
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than tripled in east Asia, from 250,000 (230,000–270,000) to 860,000 
(770,000–940,000), and more than doubled in southeast Asia, from 
110,000 (100,000–120,000) to 310,000 (290,000–330,000). As a 
result, by 2017 east, southeast and south Asia accounted for half of 
all deaths attributable to high non-HDL cholesterol, compared with 
a quarter in 1990.
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Fig. 2 | Change in age-standardized mean non-HDL cholesterol between 
1980 and 2018 by region for women and men. a, Age-standardized mean 
non-HDL cholesterol in women. b, Age-standardized mean non-HDL 
cholesterol in men. The start of the arrow shows the level in 1980 and the head 
indicates the level in 2018. See Extended Data Fig. 3 for age-standardized mean 
HDL cholesterol. One mmol l−1 is equivalent to 38.61 mg dl−1.
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Fig. 3 | Age-standardized mean non-HDL cholesterol by country in 1980 and 
2018 for women and men. a, Age-standardized mean non-HDL cholesterol in 
women in 1980. b, Age-standardized mean non-HDL cholesterol in women in 
2018. c, Age-standardized mean non-HDL cholesterol in men in 1980.  
d, Age-standardized mean non-HDL cholesterol in men in 2018. See Extended 
Data Fig. 5 for age-standardized mean total cholesterol and Extended Data 
Fig. 6 for age-standardized mean HDL cholesterol. One mmol l−1 is equivalent to 
38.61 mg dl−1.
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Implications
Our results show that over the past nearly four decades, there has been 
a major global repositioning of lipid-related risk, with non-optimal cho-
lesterol patterns shifting from being a distinct feature of high-income 
countries in northwestern Europe, north America and Australasia to one 
that affects middle-income countries in east and southeast Asia, as well 
as some countries in Oceania and central Latin America. This transition 
is especially noticeable for non-HDL cholesterol, which had not been 
quantified previously in a global analysis. This global repositioning has 
occurred as a consequence of opposing trends in high-income western 
countries and in Asia, which has led to some Asian countries having the 
highest worldwide non-HDL cholesterol levels in 2018.
The decrease in non-HDL cholesterol in western countries started 
in the 1980s, before statins were widely used15,16. This indicates that 
changes in diet, especially the replacement of saturated with unsatu-
rated fats3,17–21 and reduction in trans fats12,17,22, are major contributors 
to this decline. Nonetheless, the increased use of statins from the 
late 1990s onwards15,16, may explain up to one half of the decrease in 
those countries in which statins are widely used19,23,24. In contrast to 
high-income western countries, the consumption of animal-source 
foods, refined carbohydrates and palm oil has increased substantially 
in east and southeast Asia3,25,26, where statin use remains low13,27. For 
example, the Pearson correlation coefficient between the change in 
non-HDL cholesterol and the change in a multi-dimensional score 
of animal-source foods and sugar3 was 0.69 for women and 0.67 for 
men using data from high-income western countries and countries in 
east and southeast Asia, the two regions that experienced the largest 
decrease and increase, respectively, in non-HDL cholesterol levels. 
Finally, changes in diet, especially a decrease in carbohydrate and an 
increase in fat intake28–31, may have contributed to the large increase 
in HDL cholesterol observed in the high-income Asia–Pacific region, 
where there was little increase in overweight and obesity relative to 
other regions8,9. By contrast, the large increase in diabetes32 and adi-
posity8 in Oceania may have contributed to the decrease in HDL cho-
lesterol in this region. The Pearson correlation coefficient between 
the change in HDL cholesterol and the change in body-mass index8 was 
−0.87 for women and −0.69 for men using countries in the high-income 
Asia–Pacific region and Oceania, the two regions that had the largest 
increase and decrease, respectively, in HDL cholesterol; the Pearson 
correlation coefficient for the change in HDL cholesterol and change 
in diabetes prevalence32 was −0.84 for women and −0.69 for men. In the 
same regions, the Pearson correlation coefficient between the change 
in non-HDL cholesterol and the change in body-mass index8 was 0.77 
for women and 0.62 for men; for the change in non-HDL cholesterol 
and the change in diabetes prevalence32, the Pearson correlation coef-
ficient was 0.54 for women and 0.40 for men.
Although it has previously been documented that the prevalence of 
adiposity8,9, diabetes32 and high blood pressure33 is now higher in low- 
and middle-income countries than in high-income countries, higher 
cholesterol is commonly considered to be a feature of affluent west-
ern nations1,2. We show that, when focusing on non-HDL cholesterol, 
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middle-income countries have emerged as the new global epicentre 
of non-optimal cholesterol as they did for other major cardiovascular 
disease risk factors, indicating that there is no such a thing as a western 
risk factor. At the same time, the populations of high-income countries 
would also benefit from further lowering non-HDL cholesterol. There-
fore, population-based policies and personal interventions to improve 
nutrition and enhance treatment are now needed in all countries, espe-
cially as a part of the movement towards universal health coverage.
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Methods
Our aim was to estimate trends in mean total, HDL and non-HDL cho-
lesterol for 200 countries and territories (Supplementary Table 2). We 
used non-HDL cholesterol rather than low-density lipoprotein (LDL) 
cholesterol because most studies in our analysis had measured total 
cholesterol and HDL cholesterol, from which non-HDL cholesterol can 
be calculated through subtraction. By contrast, LDL cholesterol was 
directly measured in only around 14% of studies. When LDL cholesterol 
is not directly measured, its calculation requires data on triglycerides, 
which were available in approximately 64% of the studies. Furthermore, 
the most-commonly used estimation method—that is, the Friedewald 
equation—can be inaccurate, particularly at high levels of triglycer-
ides34. Non-HDL and LDL cholesterol were highly correlated (Pearson 
correlation coefficient = 0.94) in studies with data on both variables 
(Extended Data Fig. 9), because LDL cholesterol constitutes most of 
non-HDL cholesterol. Furthermore, non-HDL cholesterol predicts 
IHD risk at least as well as LDL cholesterol5,35, and can be measured at 
a lower cost than LDL cholesterol, which is relevant for how widely it 
can be used in low- and middle-income countries. Although non-HDL 
cholesterol is now commonly used in clinical guidelines36–38, LDL cho-
lesterol continues to be a key target for treatment36,37, possibly because 
the interpretation of non-HDL cholesterol is more complex than LDL 
cholesterol alone. Specifically, an increase in non-HDL cholesterol 
could be due to the increase in LDL cholesterol or very-low-density 
lipoprotein cholesterol39. Furthermore, there is some evidence that 
triglyceride levels are high in Asian populations, compared to levels 
seen in high-income western countries40. Therefore, data on non-HDL 
cholesterol can motivate dietary interventions to both reduce LDL 
cholesterol (for example, reducing saturated and trans fat intake) 
and triglyceride levels (for example, reducing refined carbohydrates 
and increasing omega-3 fatty acids) as well as treatments that lower 
LDL cholesterol (statins), alongside those that lower triglycerides (for 
example, fibrates).
Data sources
We used a database of population-based data on cardiometabolic risk 
factors collated by the NCD Risk Factor Collaboration (NCD-RisC), 
a worldwide network of health researchers and practitioners that 
systematically monitors the worldwide trends and variations in 
non-communicable disease (NCD) risk factors. The database was 
collated through multiple routes for identifying and accessing data. 
We accessed publicly available population-based multi-country and 
national measurement surveys (for example, Demographic and Health 
Surveys and surveys identified through the Inter-University Consor-
tium for Political and Social Research and European Health Interview 
& Health Examination Surveys Database). We requested, via the World 
Health Organization (WHO) and its regional and country offices, from 
ministries of health and other national health and statistical agen-
cies to identify and access population-based surveys. Requests were 
also sent via the World Heart Federation to its national partners. We 
made a similar request to the co-authors of an earlier pooled analysis 
of cardiometabolic risk factors7,41–43, and invited the co-authors of the 
analysis to reanalyse data from their studies and join NCD-RisC. Finally, 
to identify major sources that were not accessed through the above 
routes, we searched and reviewed published studies as described in 
the Supplementary Information and invited all eligible studies to join 
NCD-RisC.
For each data source, we recorded the available information about 
the study population, start year and duration of measurement, sam-
pling approach and measurement methods. The information about 
study population was used to establish that each data source was 
population-based, and to assess whether it covered the whole country, 
multiple subnational regions or one or a small number of communities, 
and whether it was rural, urban or combined.
We carefully checked all data sources in terms of how they met our 
inclusion and exclusion criteria listed below. We identified duplicate 
data sources by comparing studies from the same country and year. 
Additionally, all NCD-RisC members are asked periodically to review 
the list of sources from their country, to suggest additional sources not 
in the database, and to verify that the included data meet the inclusion 
criteria listed below and are not duplicates. The NCD-RisC database is 
continuously updated through the above routes and through regular 
contact with NCD-RisC members.
Anonymized individual record data from sources included in 
NCD-RisC were reanalysed according to a common protocol. Within 
each survey, we included participants aged 18 years and older who 
were not pregnant. We removed participants with implausible total 
cholesterol levels (defined as total cholesterol levels of <1.75 mmol l−1 
or >20 mmol l−1, or total cholesterol values that were lower than HDL 
cholesterol values) (<0.05% of all participants with total cholesterol 
measurements) or HDL cholesterol levels (defined as HDL cholesterol 
levels of <0.4 mmol l−1 or >5 mmol l−1, or total cholesterol values that 
were lower than HDL cholesterol values) (<0.15% of all participants with 
HDL cholesterol measurements). When data on LDL cholesterol were 
also available, we removed individuals for whom the sum of LDL and 
HDL cholesterol level surpassed total cholesterol level by more than is 
plausible based on the limits to errors in their measurement (following 
the CDC Cholesterol Reference Method Laboratory Network (CRMLN) 
standards, these errors were set at 8.9% for total cholesterol, 13% for 
HDL cholesterol and 12% for LDL cholesterol) (<0.06% of all participants 
with total cholesterol and HDL cholesterol measurements)44–46.
We calculated mean total cholesterol, mean HDL cholesterol and 
mean non-HDL cholesterol, and associated standard errors and sam-
ple sizes, by sex and age group (18–19 years, 20–29 years, followed by 
10-year age groups and 80+ years). All analyses incorporated appro-
priate sample weights and complex survey design in calculating 
age–sex-specific means when applicable. To ensure summaries were 
prepared according to the study protocol, computer code was provided 
to NCD-RisC members who requested assistance. All submitted data 
were checked independently by at least two researchers. Questions and 
clarifications were discussed with NCD-RisC members and resolved 
before the data were incorporated in the database.
Finally, we obtained data not accessed through the above routes 
by extracting data from published reports of all additional national 
health surveys identified through the above-described strategies, as 
well as eight sites of the WHO Multinational MONItoring of trends and 
determinants in CArdiovascular disease (MONICA) project that were 
not deposited in the MONICA Data Centre. Data were extracted from 
published reports only when reported by sex and in age groups no wider 
than 20 years. We also used data from a previous pooling study7 when 
such data did not overlap with those accessed through the above routes.
Data inclusion and exclusion
Data sources were included in NCD-RisC database if: (1) measured data 
on total, LDL, HDL cholesterol and/or triglycerides were available; (2) 
study participants were 10 years of age or older; (3) data were collected 
using a probabilistic sampling method with a defined sampling frame; 
(4) data were from population samples at the national, subnational 
(covering one or more subnational regions, more than three urban 
communities or more than five rural communities) or community (one 
or a small number of communities) level; (5) data were collected in or 
after 1950; and (6) data were from the countries and territories listed 
in Supplementary Table 2.
We excluded all data sources that included only hypercholesterolae-
mia or dyslipidaemia diagnosis history or medication status without 
measurement of cholesterol levels. We also excluded data sources 
on population subgroups for which the lipid profile may differ sys-
tematically from the general population, including: (1) studies that 
had included or excluded people on the basis of their health status or 
cardiovascular risk; (2) studies for which the participants were only 
from ethnic minorities; (3) studies that had recruited only specific edu-
cational, occupational or socioeconomic subgroups, with the exception 
noted below; and (4) studies that had recruited participants through 
health facilities, with the exception noted below.
We used school-based data in countries and for age–sex groups, for 
which secondary school enrolment was 70% or higher. We used data for 
which the sampling frame was health insurance schemes in countries 
in which at least 80% of the population was insured. Finally, we used 
data collected through general practice and primary-care systems in 
high-income and central European countries with universal insurance, 
because contact with the primary-care systems tends to be as good as or 
better than response rates for population-based surveys. We used data 
sources regardless of fasting status, because the differences between 
fasting and non-fasting measurements are negligible for total, non-HDL 
and HDL cholesterol39, and therefore non-fasting lipid profiles are now 
widely endorsed for the estimation of cardiovascular risk36,37.
Data used in the analysis
For this paper, we used data from the NCD-RisC database for years 
1980 to 2018 and individuals aged 18 years and older. A list of the data 
sources that we used in this analysis and their characteristics is provided 
in Supplementary Table 1. The data comprised 1,127 population-based 
measurement surveys and studies that included measurements of 
blood lipids on 102.6 million participants aged 18 years and older. 
We had at least one data source for 161 of the 200 countries that we 
made estimates for, covering 92.4% of the world’s population in 2018 
(Extended Data Fig. 1); and at least two data sources for 104 countries 
(87.5% of the world population). Of these 1,127 sources, 409 (36.3%) 
sampled from national populations, 250 (22.2%) covered one or more 
subnational regions, and the remaining 468 (41.5%) were from one or a 
small number of communities. Regionally, data availability ranged from 
around 2 data sources per country in sub-Saharan Africa to approxi-
mately 35 sources per country in the high-income Asia–Pacific region. 
In total, 454 data sources (40.3%) were from years before 2000 and the 
remaining 673 (59.7%) were collected from 2001 onwards.
Adjusting for the differences in mean cholesterol between 
portable device and laboratory measurements
In 112 (10%) of the 1,127 data sources used in our analysis (11.5% and 5.8% 
of age–sex-specific data points for total and HDL cholesterol, respec-
tively) lipids were measured using a portable device. Some portable 
devices have narrower analytical ranges than laboratory methods, 
which results in truncations of blood cholesterol data that are outside 
their range (Supplementary Table 3). This may in turn affect the popula-
tion mean. Although cholesterol concentrations that fall outside the 
analytical range are displayed as ‘high’ (above the measurement range) 
or ‘low’ (below the measurement range) by these devices, different sur-
veys record and code cholesterol concentrations outside the analytical 
range in different ways, for example using ‘too low’, ‘too high’ and ‘error’ 
codes; assigning the minimum or maximum value to individuals whose 
cholesterol was below or above the analytical range, respectively; set-
ting values outside the analytical range to missing; and so on. We used 
an approach that treated surveys with such data consistently.
Specifically, we first dropped all participants with cholesterol levels 
below and at the minimum, and at and above the maximum, values of 
the analytical range of each portable device before calculating the mean 
cholesterol (Supplementary Table 3). We then developed conversion 
regressions to adjust the mean cholesterol levels measured using a 
portable device (calculated over the restricted range, Supplementary 
Table 3) to the levels expected using laboratory measurements. The 
dependent variable in each regression was mean total, non-HDL or HDL 
cholesterol for the full range, and the main independent variable was 
mean total, non-HDL or HDL cholesterol over the above-mentioned 
restricted cholesterol range of the portable devices. The regression 
coefficients were estimated from data sources for which lipids were 
measured in a laboratory, and thus had the full range of measurement 
and could be used to calculate both dependent and independent vari-
ables. When estimating the regression coefficients, we constructed the 
dependent variable using the full data, and the independent variable 
by dropping the values outside the above-mentioned restricted cho-
lesterol range of each device, mimicking those that would be expected 
if a portable device had been used. Separate models were developed 
according to the specific range of the different portable devices. All 
regressions included terms for age and sex, as well as interactions 
between predictors and age and sex, based on the Bayesian information 
criterion47. The regressions for mean non-HDL cholesterol also included 
mean total cholesterol and mean HDL cholesterol because non-HDL 
cholesterol is calculated from total cholesterol and HDL cholesterol. 
We excluded data points for which there were fewer than 25 individu-
als for the purpose of estimating the coefficients of these regressions. 
All sources of uncertainty in the conversion—including the sampling 
uncertainty of the original data, the uncertainty of the regression coef-
ficients and residuals—were carried forward by using repeated draws 
from their respective distributions. The regression coefficients and 
number of data points used to estimate the coefficients are shown in 
Supplementary Table 4.
Statistical analysis
We used a statistical model to estimate mean total, non-HDL and HDL 
cholesterol by country, year, sex and age using all of the available data. 
The model is described in detail in a statistical paper and related sub-
stantive papers8,32,33,48; the computer code is available at http://www.
ncdrisc.org/. In summary, we organized countries into 21 regions, 
mainly based on geography and national income; these regions were 
further aggregated into 9 ‘super-regions’ (Supplementary Table 2). The 
model had a hierarchical structure in which estimates for each country 
and year were informed by its own data, if available, and by data from 
other years in the same country and from other countries, especially 
countries in the same region or super-region with data for similar 
time periods. The extent to which estimates for each country-year 
are influenced by data from other years and other countries depends 
on whether the country has data, the sample size of data, whether or 
not they are national, and the within-country and within-region data 
variability. The model incorporated nonlinear time trends comprising 
linear terms and a second-order random walk. The age association of 
blood lipids was modelled using a cubic spline to allow nonlinear age 
patterns, which might vary across countries. The model accounted for 
the possibility that blood lipids in subnational and community samples 
might systematically differ from nationally representative ones; and/
or have larger variation. These features were implemented by includ-
ing data-driven fixed-effect and random-effect terms for subnational 
and community data. The fixed effects adjust for systematic differ-
ences between subnational or community studies and national studies. 
The random effects allow national data to have larger influence on the 
estimates than subnational or community data with similar sample 
sizes. The model also accounted for rural–urban differences in blood 
lipids, through the use of data-driven fixed effects for rural-only and 
urban-only studies. These rural and urban effects were weighted by the 
difference between study-level and country-level urbanization in the 
year in which the study was done. The proportion of the national popu-
lation living in urban areas was also included as a predictor (covariate) 
in the model. The model for mean non-HDL and HDL cholesterol also 
used age-standardized mean total cholesterol as a covariate.
We fitted the statistical model with the Markov chain Monte Carlo 
(MCMC) algorithm, and obtained 5,000 post-burn-in samples from 
the posterior distribution of model parameters, which were in turn 
used to obtain the posterior distributions of mean total, non-HDL and 
HDL cholesterol. We calculated average change in mean total, HDL and 
non-HDL cholesterol across the 39 years of analysis (reported as change 
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per decade). Age-standardized estimates were generated by taking 
weighted averages of age–sex-specific estimates, using the WHO stand-
ard population. Estimates for regions and the world were calculated 
as population-weighted averages of the constituent country estimates 
by age group and sex. The reported credible intervals represent the 
2.5–97.5th percentiles of the posterior distributions. We also report 
the posterior probability that an estimated increase or decrease rep-
resents a truly increasing or decreasing trend as opposed to a chance 
observation. We performed all analyses by sex, because blood lipids 
levels and trends are different in men and women.
Validation of statistical model
We tested how well our statistical model predicts missing data, known 
as external predictive validity, in two different tests. In the first test, we 
held out all data from 10% of countries with data (that is, created the 
appearance of countries with no data where we actually had data). The 
countries for which the data were withheld were randomly selected 
from the following three groups: data rich (5 or more data sources, with 
at least one data source after the year 2000), data poor (1 data source) 
and average data availability (2–4 data sources). In the second test, we 
assessed other patterns of missing data by holding out 10% of our data 
sources, again from a mix of data-rich, data-poor and average-data 
countries, as defined above. For a given country, we either held out 
a random half of the data of a country or all of the 2000–2018 data 
of the country to determine, respectively, how well we filled in the 
gaps for countries with intermittent data and how well we estimated in 
countries without recent data. In both tests, we then fitted the model 
to the remaining 90% of the countries (test 1) or data sources (test 2) 
and made estimates of the held-out observations. We repeated each 
test five times, holding out a different subset of data in each repetition. 
In both tests, we calculated the differences between the held-out data 
and the estimates. We also calculated the 95% credible intervals of the 
estimates; in a model with good external predictive validity, 95% of 
held-out values would be included in the 95% credible intervals.
Our statistical model performed well in the external validation tests, 
that is, in estimating mean cholesterol when data were missing. The 
estimates of mean total, non-HDL and HDL cholesterol were unbiased, 
as evidenced with median errors that were very close to zero globally 
for every outcome and test, and less than ±0.30 mmol l−1 in every subset 
of withheld data except for women in the high-income Asia–Pacific 
region in test 1 for non-HDL cholesterol (median error 0.47 mmol l−1) 
and men in south Asia in test 2 for non-HDL cholesterol (median error 
−0.33 mmol l−1) (Supplementary Table 5). The 95% credible intervals 
of estimated means covered 83–92% and 75–83% of true data globally 
in the first and second tests, respectively. In subsets, coverage ranged 
from 47% to 100%, but was mostly greater than 75%, with coverage 
generally lower in test 2 than test 1. Median absolute errors ranged 
from 0.07 to 0.23 mmol l−1 globally for different outcomes and sexes, 
and were no more than 0.45 mmol l−1 in all subsets of withheld data, 
except for women in the high-income Asia–Pacific region for non-HDL 
cholesterol in test 1 (median absolute error 0.47 mmol l−1).
Calculation of the number of deaths attributable to high 
cholesterol
We estimated the number of deaths from IHD and ischaemic stroke 
attributable to high non-HDL cholesterol. For each country, year, sex 
and age group, we first calculated the population attributable frac-
tions—that is, the proportion of deaths from IHD and ischaemic stroke 
that would have been prevented if non-HDL cholesterol levels were at 
an optimal level (defined as a mean of 1.8–2.2 mmol l−1) in the popula-
tion6,49. For these calculations, we used age-specific relative risks from 
meta-analyses of prospective cohort studies4,5,50. The number of IHD 
and ischaemic stroke deaths attributable to high non-HDL cholesterol 
was calculated for each country–year–age–sex group by multiplying the 
cause-specific population attributable fractions by the cause-specific 
deaths from the Global Burden of Disease study in 1990 and 2017 (the 
earliest and latest years with cause-specific mortality data).
Strengths and limitations
The strengths of our study include its scope in making consistent and 
comparable estimates of trends in blood cholesterol and its cardio-
vascular disease mortality burden, over almost four decades for all of 
the countries in the world, including global estimates of non-HDL and 
HDL cholesterol. We used a large amount of population-based data, 
which came from countries in which 92% of the global adult population 
lives. We used only data from studies that had measured blood lipids 
to avoid bias in self-reported data. Data were analysed according to a 
consistent protocol, and the characteristics and quality of data from 
each country were rigorously verified through repeated checks by 
NCD-RisC members. We pooled data using a statistical model that 
took into account the epidemiological features of cholesterol, includ-
ing nonlinear time trends and age associations. Our statistical model 
used all available data while giving more weight to national data than 
to subnational and community sources.
Similar to all global analyses, our study is affected by some limita-
tions. Despite our extensive efforts to identify and access worldwide 
population-based data, some countries had no or few data sources, 
especially those in sub-Saharan Africa, the Caribbean, central Asia 
and Melanesia. Estimates for these countries relied mostly or entirely 
on the statistical model, which shares information across countries 
and regions through its hierarchy. Data scarcity is reflected in wider 
uncertainty intervals of our estimates for these countries and regions, 
highlighting the need for national NCD-oriented surveillance. The 
distribution of lipids measured in a population using a portable device, 
which was used in 10% of our studies, may be truncated and may there-
fore affect the population mean. To overcome this issue, we developed 
conversion regressions to adjust mean cholesterol levels measured 
using a portable device to the levels expected in laboratory measure-
ments; the conversion regressions used for this purpose had good 
predictive accuracy. Although most studies had measured cholesterol 
in serum samples, around 7% had used plasma samples. As choles-
terol measured in plasma and serum samples differ51 by only about 3%, 
adjusting for plasma-serum differences would have little effect on our 
results, as seen in a previous analysis14. Although methods to measure 
total and HDL cholesterol have evolved over time, since the 1950s there 
have been systematic efforts to standardize lipid measurements that 
have resulted in increased comparability between different methods. 
In our analysis, 90% of studies measured lipids in a laboratory; of these 
studies more than 60% for total cholesterol and more than 70% for 
HDL cholesterol participated in a lipid standardization programme 
or quality control scheme. We did not analyse emerging lipid mark-
ers such as apolipoprotein B and apolipoprotein A-I, because they are 
neither commonly measured in population-based health surveys, nor 
routinely used in clinical practice36.
Comparison with other studies
There are no global analyses on trends in lipid fractions for comparison 
with our results. Our findings for total cholesterol were largely consist-
ent with the only other previous analysis7, but we estimated a larger 
decrease in mean total cholesterol in high-income western countries 
and central Europe, and a larger increase in southeast Asia, because 
we had an additional decade of data compared with the earlier global 
analysis. Therefore, although the highest mean total cholesterol levels 
reported previously7, for 2008, were still in high-income western coun-
tries, we estimated that in 2018 total cholesterol was equally high or 
higher in southeast Asia. Our findings on mean total cholesterol trends 
are also largely consistent with previous multi- and single-country 
reports14,15,17–21,52–73. Differences from previous studies—for example, 
in Italy61, Lithuania63, the Netherlands65, Russian Federation69 and in 
some countries that participated in the MONICA Project52—mostly arise 
because our study covered a longer period and used a larger number 
of data sources. Studies15,18,54,63,66,70,74–77 that have reported trends in 
lipid fractions for a period longer than 15 years have found changes 
in non-HDL cholesterol (or in LDL cholesterol for some studies) that 
were consistent with our results.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
Estimates of mean total, non-HDL and HDL cholesterol by country, 
year and sex are available at http://www.ncdrisc.org/. Input data from 
publicly available sources can also be downloaded from http://www.
ncdrisc.org/. For other data sources, contact information for data 
providers can be obtained from http://www.ncdrisc.org/.
Code availability
The computer code for the Bayesian hierarchical model used in this 
work is available at http://www.ncdrisc.org/.
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Extended Data Fig. 1 | Number of data sources by country. The colour indicates the number of data sources for each country used in the analysis. Countries and 
territories that were not included in the analysis are coloured in grey.
Extended Data Fig. 2 | Number of data sources by region and year. The size of each circle shows the number of data sources for each region and year, and the 
colours indicate the relative size of national, subnational and community data sources.
Article
Extended Data Fig. 3 | Change in age-standardized mean HDL cholesterol between 1980 and 2018 by region for women and men. The start of the arrow 
shows the level in 1980 and the head shows the level in 2018. One mmol l−1 is equivalent to 38.61 mg dl−1.
Extended Data Fig. 4 | Change in age-standardized mean HDL and non-HDL cholesterol between 1980 and 2018 by region for women and men. One mmol l−1 
is equivalent to 38.61 mg dl−1.
Article
Extended Data Fig. 5 | Age-standardized mean total cholesterol by country in 1980 and 2018 for women and men. One mmol l−1 is equivalent to 38.61 mg dl−1.
Extended Data Fig. 6 | Age-standardized mean HDL cholesterol by country in 1980 and 2018 for women and men. One mmol l−1 is equivalent to 38.61 mg dl−1.
Article
Extended Data Fig. 7 | Change per decade in age-standardized mean total cholesterol by country for women and men. One mmol l−1 is equivalent to 
38.61 mg dl−1.
Extended Data Fig. 8 | Change per decade in age-standardized mean HDL cholesterol by country for women and men. One mmol l−1 is equivalent to 
38.61 mg dl−1.
Article
Extended Data Fig. 9 | The association between mean LDL and non-HDL cholesterol in studies that measured lipids in a laboratory that had data for both 
variables. Each data point is one study–age–sex group (n = 6,864). One mmol l−1 is equivalent to 38.61 mg dl−1.
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Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency 
in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection Processing of secondary data was conducted using the statistical software R (version 3.6.0).
Data analysis All analyses were conducting using the statistical software R (version 3.6.0). The code for estimation of mean risk factor trends is 
available at www.ncdrisc.org. 
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
This is a data-pooling study that brings together more than 1000 disparate data sources and uses a Bayesian hierarchical model to estimate population risk factor 
trends. Estimates of mean total, non-HDL and HDL cholesterol by country, year, and sex will be available from www.ncdrisc.org upon the publication of the paper. 
Some of the input data sources are publicly available, for which we will add links in the final version of the paper. Others are the property of specific research groups 
and agencies, for which we will provide contact information.
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Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Behavioural & social sciences study design
All studies must disclose on these points even when the disclosure is negative.
Study description We pooled and re-analysed population-based data that had measured blood lipids in adults to estimate trends in mean total, non-HDL 
and HDL cholesterol from 1980 to 2018 for 200 countries and territories, using a Bayesian hierarchical model.
Research sample We pooled data from 1,127 population-based studies of blood lipids conducted in 161 countries, with measurement of blood lipids in 
over 102 million adults aged 18 years and older. Studies were representative of a national, subnational or community population.
Sampling strategy We included data collected using a probabilistic sampling method with a defined sampling frame. We therefore included studies with 
simple random and complex survey designs but excluded convenience samples.
Data collection We used data on measured blood lipids to calculate mean total, non-HDL and HDL cholesterol. We excluded self-reported data.
Timing We pooled data collected from 1980 to 2018. We also included national studies for the 3 years prior to 1980 (n=1), assigning them to 
1980, so that they can inform the estimates in countries with slightly earlier national data. 
Data exclusions We excluded all data sources that included only hypercholesterolemia or dyslipidaemia diagnosis history or medication status without 
measurement of cholesterol levels. We also excluded data sources on population subgroups whose lipid profile may differ systematically 
from the general population, including: 
• studies that had included or excluded people based on their health status or cardiovascular risk; 
• studies whose participants were only ethnic minorities; 
• specific educational, occupational, or socioeconomic subgroups, with the exception noted below; 
• those recruited through health facilities, with the exception noted below. 
 
We used school-based data in countries, and in age-sex groups, where secondary school enrollment was 70% or higher. We used data 
whose sampling frame was health insurance schemes in countries where at least 80% of the population were insured. Finally, we used 
data collected through general practice and primary care systems in high-income and central European countries with universal 
insurance, because contact with the primary care systems tends to be as good as or better than response rates for population-based 
surveys. Our exclusion criteria were established at the initiation of the study to ensure all data were representative.
Non-participation Our inclusion/exclusion criteria were designed to ensure participants of the surveys included were representative of the general 
population from which each sample was drawn.
Randomization Our study is descriptive, and we did not carry out experiments.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems
n/a Involved in the study
Antibodies
Eukaryotic cell lines
Palaeontology
Animals and other organisms
Human research participants
Clinical data
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
